OnKure <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Reports Q3 2025 Results and Advances OKI-219 Clinical Trials
OnKure Therapeutics Inc. reported its third quarter 2025 financial results and provided a business update. The company announced that the first patients have been dosed in the triplet expansion arms of the PIKture-01 trial, which is evaluating OKI-219 in combination with fulvestrant and ribociclib, as well as in combination with trastuzumab and tucatinib, in patients with metastatic breast cancer. Clinical data from the single agent and fulvestrant combination arms of the PIKture-01 trial are maturing, with initial results from these and the triplet expansion arms expected in the first quarter of 2026. Significant progress was reported in OnKure's next-generation PI3Ka pan-mutant inhibitor program, with multiple candidates identified and an announcement planned for the first quarter of 2026. The company also noted an expansion into vascular malformations, with additional information to be provided in 2026. OKI-219 is OnKure's lead product candidate, described as a highly selective PI3kaH1047 mutant specific inhibitor, and is being evaluated in phase 1 clinical trials for patients with HR+ and HER2+ metastatic breast cancer.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Onkure Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-25-269468), on November 06, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.